AMTI Stock Overview
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Applied Molecular Transport Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$0.84 |
| 52 Week Low | US$0.13 |
| Beta | 2.29 |
| 1 Month Change | 46.68% |
| 3 Month Change | 67.52% |
| 1 Year Change | -26.21% |
| 3 Year Change | -99.15% |
| 5 Year Change | n/a |
| Change since IPO | -98.54% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Mar 07
We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Nov 13Applied Molecular Transport GAAP EPS of -$0.93
Aug 04Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky
Jul 27Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data
Jul 05Applied Molecular: Interesting Drug Delivery Approach For The GI Tract
May 03We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Apr 28We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Jan 08We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Aug 29Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans
Apr 05Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?
Feb 11Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Dec 21Applied Molecular Transport reports Q3 results
Nov 12Shareholder Returns
| AMTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | 0.7% | 0.6% |
| 1Y | -26.2% | -3.4% | 23.7% |
Return vs Industry: AMTI underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: AMTI underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| AMTI volatility | |
|---|---|
| AMTI Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMTI's share price has been volatile over the past 3 months.
Volatility Over Time: AMTI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 13 | Shawn Cross | www.appliedmt.com |
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects.
Applied Molecular Transport Inc. Fundamentals Summary
| AMTI fundamental statistics | |
|---|---|
| Market cap | US$10.87m |
| Earnings (TTM) | -US$74.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs AMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$42.08m |
| Gross Profit | -US$42.07m |
| Other Expenses | US$32.71m |
| Earnings | -US$74.79m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AMTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/28 00:20 |
| End of Day Share Price | 2023/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Applied Molecular Transport Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Matthew Barcus | Chardan Capital Markets, LLC |
| Christopher Howerton | Jefferies LLC |